Mirada Medical has injected funds into new AI-based imaging software to lead the transformation of radiation oncology, aiming to increase the speed and accuracy of cancer treatment planning applications, while delivering a more personalised level of care to patients.
The new £6 million investment will help to further the development of Mirada’s state of the art software algorithms and imaging applications, which help clinicians to simplify technically complex image processing tasks, thus helping them use medical images more effectively and improve cancer care.
Mark Gooding, chief technology officer at the firm, said: “Incidence of cancer is expected to increase globally by 62% by 2040. There were approximately 17 million new cancer patients worldwide in 2018 and we estimate half of them will receive radiation oncology as part of their treatment, thus potentially benefitting from this technology.
“We believe that AI can be rapidly applied to every-day laborious healthcare tasks such as contouring, enabling clinical staff to spend more of their valuable time working directly with their patients to deliver optimal healthcare outcomes.”
Mirada recently scored an industry first by gaining US Food and Drug Administration (FDA) clearance for its Deep Learning Contouring treatment planning solution, DLCExpert, which automates time-consuming critical structure contouring tasks, which are an essential part of the treatment planning process.
The software has been clinically validated and is already in daily clinical use at a number of leading hospitals and health centres around the world, including The University Medical Centre, Groningen in the Netherlands and the Institut Curie in France.